@article{ATM18592,
author = {Yoshifumi Saisho},
title = {Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions},
journal = {Annals of Translational Medicine},
volume = {6},
number = {7},
year = {2018},
keywords = {},
abstract = {Incretin-based therapy consists of two different classes of medication: glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors. Since the approval of exenatide, the first GLP-1 RA, and sitagliptin, the first DPP-4 inhibitor, by the U.S.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/18592}
}